Navigating the clinical progress of antibody-drug conjugates: Emerging opportunities and remaining challenges

Antibody-drug conjugates are among the fastest-growing anticancer therapies, delivering potent payloads directly to tumor cells with improved safety across hematologic and solid tumors. This review focuses on their biology and where the field needs to move as they expand into earlier-stage use and combinations that heighten the need for careful patient selection and toxicity management.